Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Misawa, Fuminari ^a   Shimizu, Keiko ^b   Fujii, Yasuo ^a   Miyata, Ryouji ^a   Koshiishi, Fumio ^a   Kobayashi, Mihoko ^a   Shida, Hirokazu ^a   Oguchi, Yoshiyo ^a   Okumura, Yasuyuki ^c   Ito, Hiroto ^c   Kayama, Mami ^d   Kashima, Haruo ^e  

^a Yamanashi Prefectural University   (Japan)

^b Japan   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d ST LUKE'S INTERNATIONAL UNIVERSITY   (Japan)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOOD PREFERENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INTERVIEW; INTRAABDOMINAL FAT; JAPAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PHYSICAL ACTIVITY; POLYPHARMACY; PREMETABOLIC SYNDROME; RISK ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING HABIT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; LIFESTYLE; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SCHIZOPHRENIA;

EID: 79960684945     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-118     Document Type: Article

References (27)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716. 10.1001/jama.288.21.2709, 12460094.
2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates form NHANES III. Schizophr Res 2005, 80(1):19-32. 10.1016/j.schres.2005.07.014, 16137860.
3. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89:(1-3):91-100. 10.1016/j.schres.2006.09.007, 17085018.
4. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007, 41(7):606-610. 10.1080/00048670701392841, 17558623.
5. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(2SUPPL):1-56.
6. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004, 65(4):500-508. 10.4088/JCP.v65n0408, 15119912.
7. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002, 28(1):105-109.
8. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 2003, 37:(7-8):951-955.
9. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003, 54(1):55-59. 10.1176/appi.ps.54.1.55, 12509667.
10. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999, 14(1):33-40. 10.1016/S0924-9338(99)80713-5, 10572323.
11. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999, 37:(4SUPPL Lilly): AS81-86.
12. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004, 58(2):178-183. 10.1111/j.1365-2125.2004.02102.x, 1884580, 15255800.
13. Connolly M, Kelly C. Life style and physical health in schizophrenia. Advances in Psychiatric treatment 2005, 11:125-132.
14. Ingram DG. Is the metabolic syndrome a discrete diagnostic category or the end of a continuum? Taxomertic evidence for dimensionality in the National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2009, 19(3):143-147. 10.1016/j.annepidem.2008.12.012, 19216996.
15. syndrome Ctedsfm: Definition and the diagnostic standard for metabolic syndrome. Nippon Naika Gaakai Zasshi 2005, 94(4):794-809. syndrome.
16. Inagaki A, Inada T, Fujii Y, Yagi G. Equivalent Dose of Psychortopics (in Japanese). 1999, Tokyo: Seiwa Shoten.
17. Yoshimatsu H. treatment manual for obesity (in Japanese). 2003, Tokyo: Ishiyaku shuppan.
18. Okuma K, Okuma M. behavior modification therapy. obesity. Nippon Rinsho 2003, 61:631-639.
19. Exercise and Physical Activity Guide for Health Promotion 2006 ~ To Prevent Lifestyle-related Diseases ~ . , http://www.nih.go.jp/eiken/programs/pdf/exercise_guide.pdf
20. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from recepter-binding profiles. Mol Psychiatry 2008, 13(1):27-35. 10.1038/sj.mp.4002066, 17848919.
21. Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990, 51(11):459-462.
22. Geslain-Biquez C, Vol S, Tichet J, Caradec A, D'Hour A, Balkau B. The metabolic syndrome in smokers. The D.E.S.I.R. study. Diabetes Metab 2003, 29(3):226-234. 10.1016/S1262-3636(07)70031-9, 12909810.
23. Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med 2006, 45(18):1039-1043. 10.2169/internalmedicine.45.1850, 17043374.
24. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986, 143(8):993-997.
25. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003, 183:534-539. 10.1192/bjp.183.6.534, 14645025.
26. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000, 284(20):2606-2610. 10.1001/jama.284.20.2606, 11086367.
27. , . American Diabetes Association, American Psychiatric, Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric, Association of Clinical Endocrinologists, North American Association for the Study of Obesity.